Patient teaching

• Instruct neutropenic patient to minimize infection risk by avoiding crowds, plants, and fresh fruits and vegetables.• Tell thrombocytopenic patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor.

☞ Advise patient to promptly report signs and symptoms of infection, bleeding, or peripheral neuropathy (such as numbness and tingling of feet and hands).• Tell patient to promptly report pain or burning at injection site.• Explain that temporary hair loss may occur.• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Frank Condella, President, European Region for IVAX Pharmaceuticals said, "IVAX is already benefiting from marketing and sales of Paxene in Belgium, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Sweden and United Kingdom, in partnership with Mayne Group Ltd.

Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company's business and prospects, including the risks that the collaboration with Combino Pharm SL may not achieve the results expected and may not accelerate IVAX' oncology growth in Spain; that Combino Pharm SL may not be able to ensure Paxene is included in oncology center protocols throughout Spain; that IVAX has in the past and may in the future experience difficulties in obtaining raw materials and other components necessary for the production of paclitaxel on commercially reasonable terms; and the impact of competitive products and pricing and successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions.

Nasdaq: NPRO) submitted a New Drug Application to the United States Food and Drug Administration seeking approval to manufacture and market Paxene in the United States for the treatment of Kaposi's sarcoma, an important cancer related to the immunocompromised state that accompanies AIDS.

As IVAX's exclusive supplier of raw material for Paxene, NaPro will receive revenue-related royalties based on IVAX's Paxene sales.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.